Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.82 |
| ▸ | IKBKB | O14920 | 2/20 | 0.78 |
| ▸ | MEN1 | O00255 | 5/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | HPGD | P15428 | 4/20 | 0.68 |
| ▸ | USP2 | O75604 | 2/20 | 0.68 |
| ▸ | TNNI3 | P19429 | 2/20 | 0.68 |
| ▸ | TNNT2 | P45379 | 2/20 | 0.68 |
| ▸ | TNNC1 | P63316 | 2/20 | 0.68 |
| ▸ | PTPN7 | P35236 | 11/20 | 0.63 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.63 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.63 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.60 |
| ▸ | HSPD1 | P10809 | 3/20 | 0.60 |
| ▸ | HSPE1 | P61604 | 3/20 | 0.60 |
| ▸ | CDC7 | O00311 | 3/20 | 0.59 |
| ▸ | PLK4 | O00444 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5995022 | 0.90 | KDM4D (1.00) | KDM4DIKBKBMEN1ALDH1A1KMT2A | |
| SCHEMBL9613384 | 0.88 | IKBKB (1.00) | KDM4DIKBKBMEN1ALDH1A1KMT2A | |
| SCHEMBL20272250 | 0.88 | KDM4D (0.82) | KDM4DIKBKBMEN1ALDH1A1KMT2A | |
| SCHEMBL9613294 | 0.83 | KDM4D (0.73) | KDM4DIKBKBMEN1ALDH1A1KMT2A | |
| SCHEMBL9613373 | 0.81 | IKBKB (0.85) | KDM4DIKBKBMEN1ALDH1A1KMT2A | |
| SCHEMBL9613300 | 0.81 | IKBKB (0.74) | KDM4DIKBKBMEN1ALDH1A1KMT2A | |
| SCHEMBL9613371 | 0.81 | IKBKB (0.85) | KDM4DIKBKBMEN1ALDH1A1KMT2A | |
| SCHEMBL5992672 | 0.81 | PTPN7 (0.80) | KDM4DIKBKBMEN1ALDH1A1KMT2A | |
| SCHEMBL5994781 | 0.79 | PTPN7 (0.77) | KDM4DIKBKBMEN1ALDH1A1KMT2A | |
| SCHEMBL9613319 | 0.79 | IKBKB (0.83) | KDM4DIKBKBMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353094-B2 | Substituted quinoxalines as kinase inhibitors | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150274709-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | THE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM | 2015-10-01 | — | — | US | disclosed |
| US-8993758-B2 | Substituted quinoxalines and uses thereof | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130289041-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2012071414-A2 | QUINOXALINE COMPOUNDS AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274709-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NFKBIA, RELA, MTOR | KDM4D 3685/4885IKBKB 11/4885MEN1 3589/4885 |
| US-20130289041-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NFKBIA, RELA, MTOR | KDM4D 3685/4885IKBKB 11/4885MEN1 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.